Related posts
Weekly 52-Week Low (or 52-Week High): BAM-T, IAG-T, ONC-T, CCB-X and More 52-Week Highs and Lows (Oct 02-08)Markets extend advancesTech rebounds, dividends returnThis summary was created by AI, based on 11 opinions in the last 12 months.
Experts have differing opinions on NorthWest Health Prop Real Est Inv Trust, with some expressing concern about its balance sheet and high risk, while others see potential in its income platform and expected strength going forward. The company has undergone management changes and has cut its dividend, but has also sold assets and seen benefits from lower interest rates and a new CEO. Overall, it appears NorthWest Health Prop Real Est Inv Trust is facing challenges but also taking steps towards stability and improvement.
It has a 6.2% yield and he doesn't usually put higher yielding stocks into the equity platforms. This one came from the income platform. It fell so fast because it was over-leveraged but has now sold some of its assets. It is building a base and appears to be breaking out so he has bought two of the three legs. Buy 0 Hold 5 Sell 0
(Analysts’ price target is $5.85)Cut dividend in 2023. Global scale, so riskier than a traditional Canadian REIT. High occupancy of 96%. She's concerned about pricing pressure. These types of REITs tend to underperform in first stages of a recession. High debt load. Yield is 7%.
Benefits from lower interest rates and a new CEO. Last year, they cut the dividend (which is safe as its payout ratio falls) and have sold $1.6 billion of assets. Their NAV is $9/share. Their properties serve healthcare, so are stable.
(Analysts’ price target is $5.71)Its sector should be more resilient. Multiple jurisdictions, so multiple currencies and credit risks. Too much debt. Management overhaul. Going through strategic process. Distribution may be challenged. High risk. Better off elsewhere.
Strategic review. Management changes. Multiple jurisdictions globally, not very efficient for a Canadian REIT especially with the state of its balance sheet. Lots of headwinds on balance sheet and distribution coverage. High leverage, tight coverage. Good assets, but not lots of options.
Large collection of healthcare real estate around the world. Inflation linked leases (good for income). Sticky tenants with doctors and healthcare. Problem is too much floating debt (higher interest rates). Recently replaced management team. Confident on business going forward. Expecting strength going forward. Book value is around $6-$7/share (trading around $4).
It is effectively a REIT. It is down 50% over the past year, a function of interest rate pressure. They have cut their dividend.
Healthcare property business not performing as well as anticipating. Floating rate debt very hard on business with rising interest rates. CEO has since resigned. Would recommend holding going forward.
Cut dividend. Healthcare properties around the world. Over-levered in a rising interest rate environment. Valuation imploded. Steer clear. Other distressed real estate ideas out there have more catalysts.
In flux. Founder/CEO left. Looking at strategic alternatives, possible asset sales. High leverage. A show-me story. Execution risk to sell assets and fix balance sheet in a difficult market.
Over-levered. Properties aren't performing as well. Geographic distribution requires them to be experts globally, which is a problem. CEO resigned, change in management. Whole sector's under stress, low quality gets hit harder.
Recent cut in dividend. Not expecting any more dividend cuts going forward. Does not own shares at this time. If already own shares, would recommend keeping.
Messy. Cut dividend by 55%. Good lesson on chasing a too-high dividend yield. 97% occupancy, but not enough to keep them out of financial difficulties. $4B of debt, more than 1/3 at floating rates. Giant "For sale" sign on it. Insider selling in January. Facing tax-loss selling if things don't turn around.
Lots of debt, operating in jurisdictions with currency risk. Bought stable, UK and US assets, but got caught offside with variable-rate debt cutting into cashflow. Cut distribution. Execution risk. Sold off, but don't add.
NorthWest Health Prop Real Est Inv Trust is a Canadian stock, trading under the symbol NWH.UN-T on the Toronto Stock Exchange (NWH.UN-CT). It is usually referred to as TSX:NWH.UN or NWH.UN-T
In the last year, 10 stock analysts published opinions about NWH.UN-T. 3 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for NorthWest Health Prop Real Est Inv Trust.
NorthWest Health Prop Real Est Inv Trust was recommended as a Top Pick by on . Read the latest stock experts ratings for NorthWest Health Prop Real Est Inv Trust.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
10 stock analysts on Stockchase covered NorthWest Health Prop Real Est Inv Trust In the last year. It is a trending stock that is worth watching.
On 2024-11-20, NorthWest Health Prop Real Est Inv Trust (NWH.UN-T) stock closed at a price of $4.89.
Balance sheet's really under pressure, making progress with repairing. Management shakeup, but now the new CEO's leaving in 2025. Lots of heavy work to do. Only for those with high risk tolerance. More compelling opportunities elsewhere.